Safety of anidulafungin in solid organ transplant recipients
| Autor: | J M, Aguado, E, Varo, P, Usetti, J C, Pozo, A, Moreno, M, Catalán, O, Len, M, Blanes, A, Solé, P, Muñoz, M, Montejo, T, Rey |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Adult
Graft Rejection Male medicine.medical_specialty Antifungal Agents medicine.medical_treatment Liver transplantation Anidulafungin Organ transplantation Echinocandins Young Adult Postoperative Complications Internal medicine Humans Medicine Lung transplantation Kidney transplantation Aged Retrospective Studies Heart transplantation Transplantation Hepatology medicine.diagnostic_test business.industry Organ Transplantation Middle Aged bacterial infections and mycoses medicine.disease Kidney Transplantation Liver Transplantation Surgery Mycoses Heart Transplantation Female Liver function business Liver function tests Immunosuppressive Agents Follow-Up Studies Lung Transplantation medicine.drug |
| Zdroj: | Liver Transplantation. 18:680-685 |
| ISSN: | 1527-6465 |
| Popis: | The aim of this study was the evaluation of the safety of anidulafungin in adult solid organ transplantation (SOT) recipients. During the study period (14 months), we included all consecutive SOT recipients from 14 centers who received anidulafungin for at least 48 hours for the treatment of invasive fungal infections (IFIs) or as prophylaxis. Relevant clinical and analytical information on clinical charts was reviewed. Clinical side effects, liver function tests, and serum creatinine levels were assessed at least weekly. The need for the modification of immunosuppressive drugs was also recorded by the investigators. All patients were followed for at least 1 week after the end of treatment (EOT) or until death. Eighty-six SOT recipients were evaluated (56 transplant recipients, 20 lung transplant recipients, 8 kidney transplant recipients, and 2 heart transplant recipients). Sixty-two patients (72%) received anidulafungin for prophylaxis, and 24 (28%) received anidulafungin for the treatment of IFIs [candidemia/invasive candidiasis (16) or invasive aspergillosis (8)]. At the baseline, only 5% of the patients were neutropenic ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text